EEG Spike Detection Is Changing Epilepsy Care

For decades, reading an EEG was an exercise in sustained human concentration. A neurologist — or a trained EEG technologist — would sit with hours of recorded brain activity, scrolling through page after page of waveforms, looking for the subtle abnormalities that indicate seizure activity or epilepsy. Spikes. Sharp waves. Patterns that might appear once in a 24-hour recording and disappear just as quickly.

It's painstaking work. It requires deep expertise. And because it depends entirely on the availability and focus of a skilled human reviewer, it has real practical limits — limits that have direct consequences for patients whose diagnosis or treatment depends on what's found, or missed, in that recording.

That's the clinical problem that modern EEG spike detection technology was built to solve. And the way it's being solved right now, through AI-powered platforms like LVIS Corporation's Neuromatch, is a meaningful advance in how neurological care gets delivered.

The Clinical Stakes of EEG Interpretation

To understand why EEG spike detection matters so much, it helps to understand what's at stake when it's done poorly or slowly.

Epileptic spikes — the sharp, high-amplitude waveform events that indicate abnormal electrical activity in the brain — are a primary diagnostic marker for epilepsy. Finding them in an EEG recording informs diagnosis, guides medication decisions, and shapes long-term treatment planning. Missing them means delayed diagnosis, continued seizures, and in some cases, unnecessary procedures or medications.

The challenge is that spikes don't announce themselves. They appear briefly, sometimes only once or twice across a multi-hour recording, embedded in hours of background brain activity. Traditional review workflows require clinicians to examine that entire recording manually — an enormous time investment that gets harder to sustain as patient volumes increase and the clinical workforce strains under demand.

For hospitals managing high patient volumes, the backlog of unreviewed EEGs is a real and growing problem. Studies have consistently shown that EEG review delays can stretch from hours to days, and every delay has downstream consequences for the patients waiting on results.

What AI Changes About the Process

The introduction of deep-learning algorithms to EEG analysis changes the fundamental bottleneck in this workflow. Instead of a human reviewer scanning through every minute of a recording looking for events, an AI system pre-processes the data — identifying candidate spikes and seizure events, flagging them for clinical review, and filtering out the hours of background activity that don't require attention.

This isn't about replacing neurologists. It's about changing what they spend their time on.

When a skilled clinician is freed from the manual scanning process and can focus instead on reviewing flagged events — validating, adjusting, and applying their clinical judgment to a curated set of candidate findings — the efficiency of the diagnostic process changes dramatically. More recordings can be reviewed in the same time. Review quality improves because the reviewer isn't fatigued from hours of scanning. And the time from EEG acquisition to clinical action compresses in ways that directly benefit patients.

This is the core value proposition of AI-assisted EEG spike detection — not automation for its own sake, but a redistribution of clinical effort toward the work that genuinely requires human expertise.

How NeuroMatch Approaches the Problem

LVIS Corporation's NeuroMatch platform was built from the ground up to address these clinical workflow challenges. The platform's Spike Detection feature identifies spikes and sharp wave events in 19-channel EEG data, flagging the markers that are most relevant to epilepsy diagnosis and management.

The detection algorithms underlying NeuroMatch were validated through thousands of hours of EEG recordings — a dataset scale that gives the system the pattern recognition depth needed to perform reliably across the variability of real clinical data. EEG patterns differ across patients, age groups, recording conditions, and underlying pathologies. A system trained on a narrow or homogeneous dataset will struggle with the edges; NeuroMatch was developed with that clinical reality in mind.

The FDA-cleared platform also includes Seizure Detection — using deep-learning algorithms that identify seizure events automatically and notify physicians within an hour of detection. In a monitoring context, where the window for clinical intervention can be narrow, that turnaround matters.

What sets NeuroMatch apart from earlier generation automated systems is the way it integrates physician judgment into the workflow rather than trying to replace it. Detected events are presented for clinical review — the neurologist can validate what the system found, dismiss false positives, and adjust classifications based on the full clinical context they bring to the case. The AI handles the volume; the clinician handles the decisions. That division of labor is the right one.

The Staffing and Access Dimension

There's a dimension of this technology that doesn't get enough attention in clinical discussions: access.

The United States faces a genuine shortage of neurologists and EEG-trained specialists, particularly outside major metropolitan areas. Community hospitals and rural health systems often lack the specialist staffing to maintain rapid EEG review workflows — which means patients in those settings face longer diagnostic timelines than patients in academic medical centers, through no fault of their own.

AI-assisted EEG analysis changes the access equation. When a platform like NeuroMatch can do the front-end processing — flagging spikes and seizure events, reducing the volume of recordings requiring immediate specialist attention, and enabling remote review workflows — the geographic constraints on quality neurological care begin to loosen.

A neurologist reviewing flagged events remotely can serve a patient population spread across a much wider area than the traditional in-person model allows. The quality of the diagnostic process doesn't have to degrade with distance when the technology is doing the work that previously required physical proximity.

What Good EEG Software Architecture Looks Like

Not all AI-powered EEG analysis tools are built the same way, and the differences matter clinically. The most important architectural consideration is the relationship between automated detection and human oversight.

Systems that present AI findings as definitive outputs — without clear mechanisms for clinician review and adjustment — create a different kind of risk than the one they solve. Over-reliance on automated findings, or insufficient transparency about the basis for detection, can introduce errors that are harder to catch than the ones in manual review.

The best EEG software platforms are designed with what might be called a human-in-the-loop architecture: AI handles detection and prioritization, humans handle validation and decision-making, and the system is transparent enough about its findings that clinicians can engage with them critically rather than accepting them passively.

NeuroMatch is built on this principle. The workflow keeps the neurologist in the decision-making seat while dramatically reducing the time and effort required to get there.

Where Clinical EEG Is Heading

The adoption of AI-assisted EEG analysis in the US is still relatively early. NeuroMatch launched in the United States in January 2025, after successful deployment in more than 10 hospitals in South Korea — giving the platform a real-world clinical track record that preceded its US entry. That international validation matters: it means the efficacy data behind the platform wasn't generated in controlled lab conditions but in operating clinical environments.

As more US hospitals and neurology practices integrate AI-assisted tools into their diagnostic workflows, the standard of care around EEG interpretation will shift. The question for clinical leaders isn't whether this technology becomes part of standard practice — it's how quickly their institution gets there and whether they're positioned to benefit from the efficiency and access gains early adoption enables.

The patients who benefit most are the ones whose diagnosis arrives faster, whose epileptic activity is caught earlier, and whose treatment can begin before the condition progresses. That's what this technology is ultimately in service of.

If your hospital or neurology practice is evaluating AI-powered EEG analysis tools, NeuroMatch offers FDA-cleared spike and seizure detection with a physician-centered workflow built for real clinical environments. Visit lviscorp.com to learn more or schedule a demonstration with the LVIS Corporation team.